BofA Securities has upgraded Vir Biotechnology (NASDAQ:VIR) to buy from neutral saying that the market is underestimating the company's phase 3 combo treatment for severe liver disease caused ...
・Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported. ・Gilead’s rival therapy bulevirtide ...
Hosted on MSN
Evercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation
Fintel reports that on September 3, 2025, Evercore ISI Group initiated coverage of Vir Biotechnology (NasdaqGS:VIR) with a Outperform recommendation. Analyst Price Forecast Suggests 259.55% Upside As ...
Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart and elebsiran, a combination therapy developed for chronic Hepatitis B in ...
There's a whole world under the surface and only Ron has any idea about it. And sometimes the two worlds collide, and sometimes they don't. Ron holds them at arm's length from each other. Watch every ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback